Gilead Sciences is a biopharmaceutical company headquartered in California. The company is most well-known as the maker of remdesivir, also known as Veklury, an experimental antiviral drug that may help treat the novel coronavirus.
In May, remdesivir was designated for emergency use authorization for treatment of COVID-19 by the U.S. Food and Drug Administration (FDA), which means it's being used to treat patients in emergency situations. While the drug isn't fully approved by the FDA and its efficacy and long-term effects are still being studied, this designation has generated a lot of buzz for Gilead.
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
Over the last 12 months, Gilead Sciences's shares have ranged in value from as little as $72.5394 up to $86.7523. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.336. This would suggest that Gilead Sciences's shares are less volatile than average (for this exchange).
Historical closes compared with the last close of $77.61
| 1 week (2023-11-26) | 2.96% |
|---|---|
| 1 month (2023-11-03) | -4.46% |
| 3 months (2023-09-03) | 2.24% |
| 6 months (2023-06-03) | 1.81% |
| 1 year (2022-12-03) | -9.53% |
| 2 years (2021-12-03) | 21.10% |
| 3 years (2020-12-03) | 44.08% |
| 5 years (2018-12-03) | 33.94% |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Gilead Sciences P/E ratio, PEG ratio and EBITDA
Gilead Sciences's current stock price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Gilead Sciences stocks trade at around 17x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of November 10, 2023 (20.44). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5134. A PEG ratio below 1 can be interpreted as meaning the shares are not overvalued given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $11.7 billion.
The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure a its profitability.
Everything we know about the Discord IPO, plus information on how to buy in.
Steps to owning and managing FND, with 24-hour and historical pricing before you buy.
Steps to owning and managing SWX, with 24-hour and historical pricing before you buy.
Everything we know about the Chime IPO, plus information on how to buy in.
Steps to owning and managing KEG, with 24-hour and historical pricing before you buy.
Steps to owning and managing MDR, with 24-hour and historical pricing before you buy.
Steps to owning and managing GEN, with 24-hour and historical pricing before you buy.
Everything we know about the Grail IPO, plus information on how to buy in.
Steps to owning and managing HOG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ET, with 24-hour and historical pricing before you buy.